Table 1

Age and tumor characteristics for prostate cancer patients referred for radiation therapy at Korle Bu teaching hospital during 2003-2009
Characteristic Overall cohort (n=379) Organ-confined cohort (n=251) FFbF analysis cohort (n=52)
n (%) n (%) n (%)
Age, Y
<60 78 (20.6) 55 (21.9) 10 (19.2)
60-64 89 (23.5) 66 (26.3) 13 (25.0)
65-69 95 (25.1) 69 (27.5) 17 (32.7)
70-74 76 (20.1) 46 (18.3) 9 (17.3)
>74 41 (10.8) 15 (6.0) 3 (5.8)
iPSA ng/ml
0-10.0 50 (13.2) 46 (18.3) 9 (17.3)
10.1-20.0 50 (13.2) 47 (18.7) 10 (19.2)
20.1-50.0 79 (20.8) 61 (24.3) 16 (30.8)
50.1-100.0 70 (18.5) 45 (17.9) 11 (21.2)
100.1-1000.0 73 (19.3) 40 (15.9) 5 (9.6)
>1000 7 (1.9) 2 (0.8) 1 (1.9)
Unknown 50 (13.2) 10 (4.0) --
Gleason Score
≤6 130 (34.3) 114 (45.4) 25 (48.1)
7 102 (26.9) 81 (32.3) 20 (38.5)
8 to 10 71 (18.7) 40 (15.9) 5 (9.6)
Unknown 76 (20.1) 16 (6.4) 2 (3.9)
Clinical T stage
T1 17 (4.5) 17 (6.8) --
T2 114 (30.1) 114 (45.4) 22 (42.3)
≥T3 77 (20.3) 77 (30.7) 29 (55.8)
Tx 43 (11.4) 43 (17.1) 1 (1.9)
M 128 (33.8) -- --
Risk Group
Low -- 20 (8.0) 4 (7.7)
Intermediate -- 48 (19.1) 9 (17.3)
High -- 166 (66.1) 39 (75.0)
Unknown -- 17 (6.8) --

Yamoah et al.

Yamoah et al. BMC Cancer 2013 13:23   doi:10.1186/1471-2407-13-23

Open Data